Pharmaceuticals, Biotechnology and Life Sciences
First clinical study evaluating DAV132 in patients Primary endpoint met: DAV132 was safe for use in hospitalized patients with several…
DUBLIN & VIENNA–(BUSINESS WIRE)–ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned…
PARIS–(BUSINESS WIRE)–Regulatory News: Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central…
New investor Fountain Healthcare Partners provides a further €5 M capital increase adding on the initial €39 M announced last…
Results from a phase 2 randomized trial study published today in Annals of Internal Medicine DUARTE, Calif.–(BUSINESS WIRE)–#CityofHope–Patients who underwent…
BETHESDA, Md.–(BUSINESS WIRE)–#AD–India Globalization Capital, Inc. (NYSE American: IGC) today announced financial results for the quarter ended December 31, 2019,…
Phase 2 CMV vaccine dose-confirmation study more than sixty percent enrolled mRNA-1189 to prevent infectious mononucleosis and Epstein-Barr virus (EBV)…
mRNA-3704 is Moderna’s first rare disease program to enter clinical studies CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical stage…
Data from the COSMIC-021 trial will be presented on Thursday, February 13, 2020 at the American Society of Clinical Oncology’s…
– Merck Option Agreement Expires – CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–$KALV–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical…